Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04657016 · ClinicalTrials.gov registry record · Phase 3

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
579
Enrollment target
20
Study locations

NCT04657016 is a Phase 3 study of Obesity and Overweight that has completed, run by Eli Lilly and Company. The registered enrollment target is 579 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04657016, a Phase 3 study of Obesity and Overweight, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
579 participants
Enrollment target
20
Study locations

Study Summary

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Tirzepatide
  • OTHER Placebo

Study Locations (20)

California

  • National Research Institute - Huntington Park - Huntington Park
  • National Research Institute - Wilshire - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • National Research Institute (NRI) - Santa Ana - Santa Ana
  • Encompass Clinical Research - Spring Valley
  • Diablo Clinical Research, Inc. - Walnut Creek

Florida

  • Clinical Research of South Florida - Coral Gables
  • New Horizon Research Center - Miami
  • Precision Clinical Research - Sunrise
  • Clinical Research of West Florida - Tampa
  • Metabolic Research Institute, Inc. - West Palm Beach

Idaho

  • Elite Clinical Trials - Blackfoot
  • Solaris Clinical Research - Meridian
  • Elite Clinical Trials - Rexburg

Indiana

  • American Health Network of IN, LLC - Avon
  • American Health Network of IN, LLC - Franklin
  • American Health Network of IN, LLC - Muncie

Connecticut

  • Chase Medical Research, LLC - Waterbury

Illinois

  • Evanston Premier Healthcare Research LLC - Evanston

Kansas

  • Cotton O'Neil Mulvane - Topeka

Trial Details

FieldValue
Enrollment Target 579 participants
Start Date 2021-03-29
Est. Completion 2023-05-12
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04657016

The ClinicalTrials.gov registry entry for NCT04657016 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (29% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.

NCT04657016 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Idaho.

Frequently Asked Questions

What is clinical trial NCT04657016 about?

NCT04657016 is a clinical study titled "A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program". This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

What is the current status of trial NCT04657016?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 579 participants. The study started on 2021-03-29. Estimated completion is 2023-05-12.

What conditions does trial NCT04657016 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT04657016?

The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).

Who is sponsoring clinical trial NCT04657016?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04657016 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.